Case Name: Novartis Pharms. Corp. v. Alembic Pharms. Ltd., Civ. No. 22-1395-RGA, 2023 WL 6387975 (D. Del. Sept. 29, 2023) (Andrews, J.). Drug Product and Patent(s)-in-Suit: Entresto®.
As part of the Hatch-Waxman Act, given the lack of information on the allegedly infringing product, courts have found that patentees can satisfy the pleading requirements of.
U.S. District Court for the Eastern District of Louisiana - Plaintiff Felton Robichaux brought this asbestos-related lawsuit claiming he was exposed to asbestos through his work.
On the heels of the Sixth Circuit's recent decision in Martin v. Hathaway, previously discussed on Health Law Observer, a critical issue in that case, i.e., the meaning of the term "remuneration" for purposes.